Last reviewed · How we verify
Mannosylstreptomycin (Streptomycin B)
Mannosylstreptomycin (generic name: Streptomycin B) is a Streptomycin B drug. It is currently in unknown development.
Mannosylstreptomycin works by binding to the 30S subunit of the bacterial ribosome, preventing the attachment of transfer RNA and thereby inhibiting protein synthesis.
Mannosylstreptomycin is a small molecule inhibitor of the bacterial 70S ribosome. It belongs to the drug class of inhibitors and is a synthetic version of streptomycin, with the chemical name being a sulfate salt of streptomycin.
At a glance
| Generic name | Streptomycin B |
|---|---|
| Drug class | Streptomycin B |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like factories that build proteins to keep you healthy. Mannosylstreptomycin is like a key that locks the factory door, preventing the bacteria from making the proteins they need to grow and multiply.
Approved indications
Common side effects
Key clinical trials
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants (PHASE3)
- The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial (PHASE4)
- Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial (PHASE4)
- Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
- A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients. (NA)
- AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery (PHASE1,PHASE2)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients . (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mannosylstreptomycin CI brief — competitive landscape report
- Mannosylstreptomycin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Mannosylstreptomycin
What is Mannosylstreptomycin?
How does Mannosylstreptomycin work?
What is the generic name of Mannosylstreptomycin?
What drug class is Mannosylstreptomycin in?
What development phase is Mannosylstreptomycin in?
Related
- Drug class: All Streptomycin B drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing